| Dr Mark Robinson Chandler, MD | |
|
800 N Justice St, Hendersonville, NC 28791 | |
| (828) 696-1000 | |
| (828) 696-1314 |
| Full Name | Dr Mark Robinson Chandler |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 11 Years |
| Location | 800 N Justice St, Hendersonville, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073952081 | NPI | - | NPPES |
| 19VDW | Other | NC | BCBS NC |
| NN0741A | Other | NC | MEDICSARE |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Lukes Hospital | Columbus, NC | Hospital |
| Margaret R Pardee Memorial Hospital | Hendersonville, NC | Hospital |
| Park Ridge Health | Hendersonville, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Henderson County Hospital Corporation | 8123938115 | 177 |
| St. Luke's Hospital Inc | 1254324585 | 16 |
| Wake Forest Emergency Providers | 7012819816 | 218 |
News Archive
Alnylam Pharmaceuticals, Inc. has announced that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease (alpha-1 liver disease).
Saint Louis University Liver Center scientists are presenting research today on a more effective way to treat hepatitis C patients who have been unresponsive to current drug therapies.
The majority of men who receive one of the standard treatments for localized prostate cancer - surgery or radiation therapy - have an excellent outcome.
Sherwin-Williams Chemical Coatings Division is raising the bar for quality coatings by partnering with Microban International, the global leader in built-in antimicrobial protection, to offer select liquid and powder product finishes with Microban(R) antimicrobial protection. Microban(R) protection works continuously to inhibit the growth of bacteria that can cause stain, odor, discoloration and deterioration of the painted surface.
› Verified 3 days ago
| Entity Name | Henderson County Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447444559 PECOS PAC ID: 8123938115 Enrollment ID: O20040611001396 |
News Archive
Alnylam Pharmaceuticals, Inc. has announced that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease (alpha-1 liver disease).
Saint Louis University Liver Center scientists are presenting research today on a more effective way to treat hepatitis C patients who have been unresponsive to current drug therapies.
The majority of men who receive one of the standard treatments for localized prostate cancer - surgery or radiation therapy - have an excellent outcome.
Sherwin-Williams Chemical Coatings Division is raising the bar for quality coatings by partnering with Microban International, the global leader in built-in antimicrobial protection, to offer select liquid and powder product finishes with Microban(R) antimicrobial protection. Microban(R) protection works continuously to inhibit the growth of bacteria that can cause stain, odor, discoloration and deterioration of the painted surface.
› Verified 3 days ago
| Entity Name | St. Luke's Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497944912 PECOS PAC ID: 1254324585 Enrollment ID: O20050103001010 |
News Archive
Alnylam Pharmaceuticals, Inc. has announced that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease (alpha-1 liver disease).
Saint Louis University Liver Center scientists are presenting research today on a more effective way to treat hepatitis C patients who have been unresponsive to current drug therapies.
The majority of men who receive one of the standard treatments for localized prostate cancer - surgery or radiation therapy - have an excellent outcome.
Sherwin-Williams Chemical Coatings Division is raising the bar for quality coatings by partnering with Microban International, the global leader in built-in antimicrobial protection, to offer select liquid and powder product finishes with Microban(R) antimicrobial protection. Microban(R) protection works continuously to inhibit the growth of bacteria that can cause stain, odor, discoloration and deterioration of the painted surface.
› Verified 3 days ago
| Entity Name | Wake Forest Emergency Providers |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396216735 PECOS PAC ID: 7012819816 Enrollment ID: O20190312003619 |
News Archive
Alnylam Pharmaceuticals, Inc. has announced that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease (alpha-1 liver disease).
Saint Louis University Liver Center scientists are presenting research today on a more effective way to treat hepatitis C patients who have been unresponsive to current drug therapies.
The majority of men who receive one of the standard treatments for localized prostate cancer - surgery or radiation therapy - have an excellent outcome.
Sherwin-Williams Chemical Coatings Division is raising the bar for quality coatings by partnering with Microban International, the global leader in built-in antimicrobial protection, to offer select liquid and powder product finishes with Microban(R) antimicrobial protection. Microban(R) protection works continuously to inhibit the growth of bacteria that can cause stain, odor, discoloration and deterioration of the painted surface.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mark Robinson Chandler, MD 800 N Justice St # 16, Hendersonville, NC 28791-3410 Ph: (828) 694-8350 | Dr Mark Robinson Chandler, MD 800 N Justice St, Hendersonville, NC 28791 Ph: (828) 696-1000 |
News Archive
Alnylam Pharmaceuticals, Inc. has announced that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease (alpha-1 liver disease).
Saint Louis University Liver Center scientists are presenting research today on a more effective way to treat hepatitis C patients who have been unresponsive to current drug therapies.
The majority of men who receive one of the standard treatments for localized prostate cancer - surgery or radiation therapy - have an excellent outcome.
Sherwin-Williams Chemical Coatings Division is raising the bar for quality coatings by partnering with Microban International, the global leader in built-in antimicrobial protection, to offer select liquid and powder product finishes with Microban(R) antimicrobial protection. Microban(R) protection works continuously to inhibit the growth of bacteria that can cause stain, odor, discoloration and deterioration of the painted surface.
› Verified 3 days ago
Dr. Roger Clay Vanarsdell, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 275 Canterbury Way, Hendersonville, NC 28792 Phone: 828-681-1839 | |
Robert J. Bryant, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 212 Thompson St Ste A, Hendersonville, NC 28792 Phone: 828-697-3232 Fax: 828-698-0125 | |
Gary R Whitaker, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 212 Thompson St Ste A, Hendersonville, NC 28792 Phone: 828-697-3232 | |
Gabriela Ursin, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 800 N Justice St, Hendersonville, NC 28791 Phone: 828-696-1000 Fax: 828-696-1314 | |
Clinton W Hamrick, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 212a Thompson St, Hendersonville, NC 28792 Phone: 828-697-3232 Fax: 828-698-0125 | |
Dr. Serena Famatta York, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 800 N Justice St, Hendersonville, NC 28791 Phone: 828-696-1000 Fax: 828-696-1314 |